Overview

A Study to Evaluate the Safety and Activity of Belvarafenib as a Single Agent and in Combination With Either Cobimetinib or Cobimetinib Plus Atezolizumab in Patients With NRAS-mutant Advanced Melanoma.

Status:
Recruiting

Trial end date:
2024-11-11

Target enrollment:

Participant gender:

Summary

This study will evaluate the safety, pharmacokinetics, and activity of belvarafenib as a single agent and in combination with either cobimetinib or cobimetinib plus atezolizumab in patients with NRAS-mutant advanced melanoma who have received anti-PD-1/PD-L1 therapy.

Phase:

Phase 1

Details

Lead Sponsor:

Genentech, Inc.

Treatments:

Atezolizumab